BD makes Vincent Forlenza CEO
This article was originally published in Clinica
Executive Summary
Becton Dickinson has appointed company stalwart and current president Vincent Forlenza to the additional role of CEO, effective 1 October. He replaces Edward Ludwig, who has been BD's CEO since 2000, and will serve as executive chairman of the board until June 2012. The appointment is the culmination of BD's long-term succession planning, which it started in 2008 when Mr Forlenza was promoted to president, where he was responsible for the medical, diagnostics and biosciences divisions, international and quality operations (www.clinica.co.uk, 11 November 2008). Mr Forlenza, who has been at BD since 1980, also became chief operating officer in July 2010. Meanwhile, BD has declared a quarterly dividend of $0.41 per share, payable on 30 September, to shareholders on the register on 9 September. The company is due to report its third-quarter financial results on 2 August.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.